More precisely, one of the patients with NSCLC received anti-EGFR-targeted therapy concomitant to re-SRS and regarding the patients with breast cancer, all of the 5 patients with hormone-dependent tumors had an ongoing anti-hormone treatment and 3 out of 7 Her-2-positive patients an ongoing anti-Her-2-therapy. This evidence concerns the gene EGFR and breast carcinoma.